• Mutation; VGNC; 54284; CCND3; Simple; p.Ala66_Ser67del (c.194_199delGCGCCA); Zygosity=Homozygous (PubMed=31175136).
  
• Mutation; VGNC; 42422; KIT; Unexplicit; Tandem duplication of a 48bp sequence; Zygosity=Unspecified (PubMed=10210327).
  
• Mutation; VGNC; 47719; TP53; Simple; p.Val162Ala (c.485T>C); Zygosity=Homozygous (PubMed=31175136).
  

PubMed=2431625; DOI=10.1152/ajpcell.1986.251.6.C935
Lazarus S.C., DeVinney R., McCabe L.J., Finkbeiner W.E., Elias D.J., Gold W.M.
Isolated canine mastocytoma cells: propagation and characterization of two cell lines.
Am. J. Physiol. 251:C935-C944(1986)

PubMed=2121170; DOI=10.1165/ajrcmb/3.5.413
DeVinney R., Gold W.M.
Establishment of two dog mastocytoma cell lines in continuous culture.
Am. J. Respir. Cell Mol. Biol. 3:413-420(1990)

PubMed=1634619; DOI=10.1172/JCI115853; PMCID=PMC443060
Pennington D.W., Lopez A.R., Thomas P.S., Peck C., Gold W.M.
Dog mastocytoma cells produce transforming growth factor beta 1.
J. Clin. Invest. 90:35-41(1992)

PubMed=10210327; DOI=10.1016/S0301-472X(98)00075-7
London C.A., Galli S.J., Yuuki T., Hu Z.-Q., Helfand S.C., Geissler E.N.
Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.
Exp. Hematol. 27:689-697(1999)

PubMed=19185923; DOI=10.1016/j.vetimm.2008.12.023
Elders R.C., Baines S.J., Catchpole B.
Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Vet. Immunol. Immunopathol. 130:11-16(2009)

PubMed=25190452; DOI=10.1186/s12917-014-0184-9; PMCID=PMC4172958
Pang L.Y., Argyle S.A., Kamida A., Morrison K.O., Argyle D.J.
The long-acting COX-2 inhibitor mavacoxib (Trocoxil TM) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro.
BMC Vet. Res. 10:184.1-184.11(2014)

PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608
Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.
Intrinsic radiosensitivity and cellular characterization of 27 canine cancer cell lines.
PLoS ONE 11:E0156689-E0156689(2016)

PubMed=26842912; DOI=10.1111/vco.12197
Hartley G., Faulhaber E.A., Caldwell A., Coy J., Kurihara J.N., Guth A., Regan D.P., Dow S.W.
Immune regulation of canine tumour and macrophage PD-L1 expression.
Vet. Comp. Oncol. 15:534-549(2017)

PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225
Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.
The Flint Animal Cancer Center (FACC) canine tumour cell line panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.
Vet. Comp. Oncol. 15:481-492(2017)

PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748
Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.
Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing.
Mol. Cancer Ther. 18:1460-1471(2019)